

Bill Summary

AB 1570 proposes required coverage without cost sharing of supplemental screening and diagnostic imaging for the detection of breast cancer.

Services in scope include: 2D mammography, DBT, breast ultrasound, CEM, MRI, MBI, biopsy, and pathology evaluation.



Insurance Subject to the Mandate

All 22.8M enrollees in state-regulated health insurance in California have insurance subject to AB 1570.

- CDI and DMHC-Regulated (Commercial and CalPERS)
- Medi-Cal

Medical Effectiveness

Very strong evidence that DBT is medically effective for screening and diagnostic use to detect breast cancer.

Some to strong evidence that ultrasound, MRI, and CEM are effective for screening and diagnostic use to detect breast cancer.

Some evidence that MBI is medically effective for screening, but **Not enough** research for its use as a diagnostic tool.

California Health Benefits Review Program (**CHBRP**), digital breast tomosynthesis (**DBT**), contrast-enhanced mammography (**CEM**), molecular resonance imaging (**MRI**), molecular breast imaging (**MBI**)

Benefit Coverage

Existing benefit coverage without cost sharing for:

Women at any level of risk of breast cancer:



primary screening mammography

Women at average risk of breast cancer following a screening:



supplemental screening



diagnostic imaging



biopsy & pathology evaluation

Postmandate additional benefit coverage without cost sharing for:

Women at any level of risk of breast cancer without a primary screening:



diagnostic imaging



supplemental screening



diagnostic imaging



biopsy & pathology evaluation

Utilization and Expenditures



AB 1570 would result in **66,384** additional screenings, diagnostic images, biopsies, and pathology evaluations for fewer than **40,263 women**.



Total annual premiums would increase by **\$93,957,000**



Average premiums would increase by **\$0.003-\$0.64*** per member per month
*variation by market segment



Newly covered benefit users would save an average of **\$85.17*** annually in enrollee expenses
*variation by market segment

Public Health Impacts

Unknown impact* on breast cancer morbidity and mortality for

1,840 additional enrollees

who would avoid a delayed breast cancer diagnosis

*unknown due to unknown types and stages of breast cancers diagnosed